Business Context and Reporting Period
This Form 8-K is a current report filed by Imprimis Pharmaceuticals, Inc. (not Harrow, Inc., as indicated in the metadata request) on November 15, 2016, regarding events occurring on November 14, 2016. The filing serves to announce the Company's financial results for the third quarter ended September 30, 2016, and to provide Regulation FD disclosure regarding a management presentation used at investor conferences.
Key Financial Metrics
The filing text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the press release furnished as Exhibit 99.1, which is not included in the provided source text.
Material Changes
The filing does not detail specific material changes versus the prior comparable period. It solely references the issuance of a press release containing the third-quarter results.
Guidance, Outlook, and Risks
The Company furnished a management presentation (Exhibit 99.2) describing the Company at investor meetings. The filing explicitly states that the information provided in Items 2.02 and 7.01, including the exhibits, is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless specifically stated. The Company assumes no obligation to update this information in the future.
Investor Verification Checklist
- Verify the actual financial figures (revenue, net loss, cash position) by reviewing the attached press release (Exhibit 99.1), as they are not present in the 8-K text.
- Confirm the company name is Imprimis Pharmaceuticals, Inc., noting the discrepancy with the "Harrow, Inc." metadata provided in the request.
- Review the management presentation (Exhibit 99.2) for qualitative outlook and strategic updates.
- Note that the information in this filing is not subject to the liabilities of Section 18 of the Exchange Act.